Regulatory Changes and Compliance Risk: The pharmaceutical industry in China is heavily regulated. Changes in drug approval processes, pricing policies, manufacturing standards, or reimbursement lists could significantly impact SUGP's operations and profitability, particularly from government-led centralized procurement programs.

Product Development and Commercialization Risk: SUGP's future growth depends on its ability to successfully research, develop, obtain approval for, and commercialize new pharmaceutical products. Failures in clinical trials, delays in regulatory approval, or lack of market acceptance for new drugs could severely impact their pipeline and financial performance.

Intense Market Competition Risk: The Chinese pharmaceutical market is highly fragmented and intensely competitive. SUGP faces competition from large domestic and international pharmaceutical companies, as well as smaller biotech firms, which could lead to pricing pressures, aggressive marketing, and erosion of market share.